AMGEN INC

Amgen's Q1 2026 institutional ownership is a $147.6B book across 3,019 holders. BlackRock is the largest holder at $16.6B (47.1M shares, -0.6% shares, slight value increase +$1.1B due to appreciation); Vanguard combined across three reporting entities totals $18.6B (Vanguard Capital Management $12.3B NEW, Vanguard Portfolio Management $5.1B NEW, Vanguard Fiduciary Trust $1.1B NEW). Capital World Investors was the largest buyer, surging +26.8% in shares to $10.3B (+$2.7B from $7.5B). JPMorgan Chase made the most dramatic active-manager increase, more than tripling shares +217.1% (2.3M to 7.3M) for a +$1.8B add to $2.5B. Capital Research Global added +49.5% shares (+$926M to $2.4B). Geode added +$747M; Charles Schwab +$628M; UBS AM +$177M; Legal & General +$114M; Nuveen +$207M. The largest seller was Capital International Investors, slashing -60.8% in shares (18.2M to 7.1M) for -$3.4B (from $5.9B to $2.5B). Wells Fargo trimmed slightly; Primecap trimmed slightly; BNY Mellon trimmed; Goldman Sachs trimmed; RBC trimmed; Bank of America trimmed. The Q1 2026 flow shows strong active-manager conviction in Amgen, with Capital World and JPMorgan the standout buyers and Capital International the most notable reduction. The 75.50 whaleScore reflects AUM. Smart-money-signal read: Amgen's Q1 2026 holder picture is net-bullish from active managers, with Capital World's +26.8% surge (+$2.7B) and JPMorgan's extraordinary +217% add as the strongest conviction signals. Capital International's -60.8% slash is the largest bearish move but likely reflects a sector-rotation or mandate change rather than a company-specific view.